Texas Biomedical Research Institute focuses on basic and translational research to advance human health and eradicate infectious diseases. It has a history of developing significant therapies and vaccines.

Texas Biomedical Research Institute

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics is a global late stage-clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases

Biomedical Advanced Research and Development Authority (BARDA)

Arcturus Therapeutics

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update 
and Pipeline Progress.

https://lnkd.in/eAgf78gv

#nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTCD #CF #ClinicalTrial #RareDiseases #Innovation #FinancialResults #Arcturus #ARCT $ARCT


We are delighted to announce that Arcturus Therapeutics was named on Deloitte's list of North America's most innovative, fastest-growing companies.
https://lnkd.in/ev8PTq8

#Fast500 #nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTC #CF #RareDiseases #Innovation #ARCT #Arcturus $ARCT

Dr. Igor Smolenov, Arcturus Therapeutics' Chief Development Officer is presenting at the 11ᵗʰ International mRNA Health Conference on Wednesday, November 1, 2023.
#Coronavirus #Vaccine #mRNA #RareDisease #ClinicalTrial #NextGenmRNA #mRNAhealthconference #mRNAconference #saRNA #mRNA2023 #Innovation #Arcturus $ARCT

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023. 
#nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTC #CF #ClinicalTrial #RareDiseases #Innovation #FinancialResults #ARCT $ARCT



Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences. $ARCT

Metric
Company Name	Texas Biomedical Research Institute
Symbol
MSH ID	ORG:TXBIOMED
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Research and Development
Country	US
Stage
Employee Count
Website	txbiomed.org
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ARCTURUSRX

Arcturus Therapeutics

Last Close

17.07

22/11 21:00

Market Cap

585.23M

Beta: -

Volume Today

512.97K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue